Pelacarsen Fails to Meet Primary Endpoint in Phase 3 Cardiovascular Trial

Novartis and Ionis Pharmaceuticals' RNA drug, pelacarsen, failed to meet its primary endpoint in a multiyear Phase 3 clinical trial. The study, involving over 8,000 participants, found that pelacarsen did not significantly reduce major cardiovascular events despite effectively lowering Lp(a) levels. This outcome raises questions about the efficacy of targeting Lp(a) for cardiovascular health protection.